Cargando…
Update in Molecular Testing for Intraocular Lymphoma
SIMPLE SUMMARY: The diagnosis of primary vitreoretinal lymphoma and central nervous system lymphoma is challenging. Intraocular biopsy and molecular testing are important for the diagnosis of cases with intraocular involvement. Intraocular biopsy does not always result in a tissue diagnosis. There a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558525/ https://www.ncbi.nlm.nih.gov/pubmed/36230469 http://dx.doi.org/10.3390/cancers14194546 |
_version_ | 1784807461113298944 |
---|---|
author | Heiferman, Michael J. Yu, Michael D. Mruthyunjaya, Prithvi |
author_facet | Heiferman, Michael J. Yu, Michael D. Mruthyunjaya, Prithvi |
author_sort | Heiferman, Michael J. |
collection | PubMed |
description | SIMPLE SUMMARY: The diagnosis of primary vitreoretinal lymphoma and central nervous system lymphoma is challenging. Intraocular biopsy and molecular testing are important for the diagnosis of cases with intraocular involvement. Intraocular biopsy does not always result in a tissue diagnosis. There are many new molecular tests that are currently being used to improve the yield of intraocular biopsy. This article will review the available molecular tests for intraocular lymphoma. ABSTRACT: The diagnosis of primary vitreoretinal lymphoma and central nervous system lymphoma is challenging. In cases with intraocular involvement, vitreous biopsy plays a pivotal role. Several diagnostic tests are employed to confirm a diagnosis and include cytologic evaluation, immunohistochemistry, flow cytometry, and cytokine analysis. The limitations of these conventional diagnostic tests stem from the often paucicellular nature of vitreous biopsy specimens and the fragility of malignant cells ex vivo. Several emerging molecular techniques show promise in improving the diagnostic yield of intraocular biopsy, possibly enabling more accurate and timely diagnoses. This article will review existing diagnostic modalities for intraocular lymphoma, with an emphasis on currently available molecular tests. |
format | Online Article Text |
id | pubmed-9558525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95585252022-10-14 Update in Molecular Testing for Intraocular Lymphoma Heiferman, Michael J. Yu, Michael D. Mruthyunjaya, Prithvi Cancers (Basel) Review SIMPLE SUMMARY: The diagnosis of primary vitreoretinal lymphoma and central nervous system lymphoma is challenging. Intraocular biopsy and molecular testing are important for the diagnosis of cases with intraocular involvement. Intraocular biopsy does not always result in a tissue diagnosis. There are many new molecular tests that are currently being used to improve the yield of intraocular biopsy. This article will review the available molecular tests for intraocular lymphoma. ABSTRACT: The diagnosis of primary vitreoretinal lymphoma and central nervous system lymphoma is challenging. In cases with intraocular involvement, vitreous biopsy plays a pivotal role. Several diagnostic tests are employed to confirm a diagnosis and include cytologic evaluation, immunohistochemistry, flow cytometry, and cytokine analysis. The limitations of these conventional diagnostic tests stem from the often paucicellular nature of vitreous biopsy specimens and the fragility of malignant cells ex vivo. Several emerging molecular techniques show promise in improving the diagnostic yield of intraocular biopsy, possibly enabling more accurate and timely diagnoses. This article will review existing diagnostic modalities for intraocular lymphoma, with an emphasis on currently available molecular tests. MDPI 2022-09-20 /pmc/articles/PMC9558525/ /pubmed/36230469 http://dx.doi.org/10.3390/cancers14194546 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Heiferman, Michael J. Yu, Michael D. Mruthyunjaya, Prithvi Update in Molecular Testing for Intraocular Lymphoma |
title | Update in Molecular Testing for Intraocular Lymphoma |
title_full | Update in Molecular Testing for Intraocular Lymphoma |
title_fullStr | Update in Molecular Testing for Intraocular Lymphoma |
title_full_unstemmed | Update in Molecular Testing for Intraocular Lymphoma |
title_short | Update in Molecular Testing for Intraocular Lymphoma |
title_sort | update in molecular testing for intraocular lymphoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558525/ https://www.ncbi.nlm.nih.gov/pubmed/36230469 http://dx.doi.org/10.3390/cancers14194546 |
work_keys_str_mv | AT heifermanmichaelj updateinmoleculartestingforintraocularlymphoma AT yumichaeld updateinmoleculartestingforintraocularlymphoma AT mruthyunjayaprithvi updateinmoleculartestingforintraocularlymphoma |